Ixifi 100 mg, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

7680697210017 CH-69721 Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

Associated product:

IXIFI subst seche 100 mg 1 pce

No image available

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
08/11/2025
Summary of Product Characteristics
Français
08/11/2025
Summary of Product Characteristics
Italien
08/11/2025

Detailed composition

Substance Quantity Type Category
infliximabum
100.0 MG Substance Wirkstoff (Principe actif)
dinatrii succinas hexahydricus
- Substance HNIDK
natrium
1.03 MG Substance HBESI
acidum succinicum
- Substance HNIDK
saccharum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK

Reimbursement information

Public price
CHF 554.75
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/09/2026

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
69721
Drug name
Ixifi, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
Galenic form
PULPI
ATC Code
L04AB02
Authorization status
Z
Dispensing category
A
First authorization
25/09/2025
Authorization expiration date
24/09/2030
IT Number
07.15.0.
Domain
Human medicine
Field of application
Rheumatoide Arthritis, Psoriatische Arthritis, Morbus Bechterew/Ankylosierende Spondylitis, Morbus Crohn, Colitis ulcerosa, Psoriasis

Package details

Description (FR)
IXIFI subst seche 100 mg 1 pce
Description (DE)
IXIFI Trockensub 100 mg 1 Stk
Market launch
01/08/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data